T he Arthus reaction is the classic in vivo model for immune complex (IC) 4 -mediated acute inflammatory tissue injury. In the reverse passive Arthus (RPA) reaction, an excess of Ab is injected into the skin of animals previously infused i.v. with the corresponding Ag. This ensures perivascular deposition of ICs in the dermis and reproducibly elicits a rapid inflammatory response characterized, in order, by edema, neutrophilia, hemorrhage, and finally tissue necrosis (reviewed in Ref. 1) . The events that initiate and propagate inflammatory tissue injury during the RPA reaction have been the subject of many studies using rabbits (2) , guinea pigs (3), and rats (4) . These early animal studies led to general agreement that complement activation by ICs is the key initiating step and demonstrated a requirement for neutrophils and mast cells for propagation of the inflammatory cascade. However, more recent studies have suggested that IC-mediated inflammation in the RPA reaction is initiated via Fc␥ receptor-triggered pathways. For example, treatment of rats with recombinant soluble human Fc␥RII was shown to lead to a dose-dependent inhibition of the RPA response (5) , and targeted deletion of the FcR ␥-chain resulted in markedly attenuated RPA reactions in mice (6, 7) . In addition, it was reported that in mice deficient in complement proteins C3, C4, or C5 the RPA reaction develops normally (8) . Thus, it was proposed that IC-initiated inflammation in the RPA response relies on activation of cellular responses triggered by Fc␥Rs and does not require complement activation (8) . Subsequent experiments utilizing mice deficient only in Fc␥RIII indicated that this receptor is involved in mediation of the RPA reaction (9) . However, in contrast to the studies using mice deficient in the ␥-chain of FcR, experiments using Fc␥RIII-deficient animals indicated that in addition to Fc␥R-triggered pathways, complement activation also contributes significantly to the mediation of the RPA reaction. Höpken et al. (10) who used mice deficient in the C5a receptor also demonstrated that complement contributes to the RPA reaction.
Obviously, the exact roles of Fc␥Rs and complement in the RPA reaction remain equivocal. Nevertheless, the combined data suggested to us that the degree of dependence on complement-and Fc␥R-mediated pathways in IC-induced injury is species specific. We tested this hypothesis by directly comparing the RPA reactions elicited in the skin of normocomplementemic and decomplemented rats, guinea pigs, and mice and found that the contribution of complement in the early edematous phase of inflammation indeed exhibits species specificity; in rats and guinea pigs complement plays a major role, whereas in C57BL/6J mice no requirement for complement could be demonstrated. In addition, using the rat model, we show that complement is activated systemically during the dermal RPA reaction and that treatment with the serine protease inhibitor BCX 1470 blocks the inflammatory response. This therapeutic effect of BCX 1470, and perhaps of other similar inhibitors, may prove useful for the treatment of human diseases where tissue injury is initiated by IC deposition and is mediated by complement activation.
Materials and Methods

Animals
All animals were fed and watered ad libitum and maintained according to protocols established by the Animal Resources Program at the University of Alabama at Birmingham. Eight-week-old C57BL/6J mice (The Jackson Laboratory, Bar Harbor, ME) weighing 30 Ϯ 2 g, 12-wk-old Sprague Dawley rats (Charles River Laboratories, Boston, MA) weighing 343 Ϯ 15 g, and 18-wk-old HsdPoc:DH guinea pigs (Harlan Sprague-Dawley, Indianapolis, IN) weighing 278 Ϯ 4 g were used.
Materials
Polyclonal rabbit anti-sheep RBC serum, chicken egg albumin (grade VII), Evans blue dye, 5,5Ј-dithiobis (2-nitrobenzoic acid), Na-benzoyl-L-Argnitroanilide, properdin, and DMSO were from Sigma (St. Louis, MO). Benzyloxycarbonyl-Lys-thiobenzyl was from Nova Biochem (La Jolla, CA), bovine trypsin was from Worthington Biochemical (Freehold, NJ), and human C1s was from Calbiochem (San Diego, CA). Cobra venom factor from Naja naja (CoVF) was from Quidel (San Diego, CA), and sheep and guinea pig erythrocytes were from Colorado Serum (Denver, CO). Polyclonal rabbit anti-chicken egg albumin IgG was from Cappel Laboratories (Cochranville, PA). The human complement proteins C3, factor B, and factor D were purified as detailed elsewhere (11) (12) (13) . BCX 1470 (2-amidino-6-[2-thiophene carboxy] benzothiophene methanesulfonate; C 14 H 10 N 2 O 2 S 2 ) was synthesized by BioCryst Pharmaceuticals (Birmingham, AL) and dissolved in DMSO for in vitro analyses or in 5% dextrose for in vivo use. Complete details of the structure and synthesis of BCX 1470 have been described elsewhere (14) .
Determination of the esterolytic activity of factor D, C1s, and trypsin
The esterolytic activity of factor D, C1s, and trypsin was determined by measurement of their ability to hydrolyze appropriate synthetic substrates (15, 16) . All esterolytic assays utilized 1.29 mM of substrate dissolved in 0.1 mM HEPES, 0.5 M NaCl, and 10% DMSO and were performed in 96-well microtiter plates (200 l per reaction). In these assays, hydrolysis of the substrate benzyloxycarbonyl-Lys-thiobenzyl by factor D (104 nM) or by C1s (3-13 nM) liberates an active group which reacts with the chromogen 5,5Ј-dithiobis (2-nitrobenzoic acid), whereas trypsin hydrolyzes the chromogenic substrate Na-benzoyl-L-Arg-nitroanalide. In both cases the change in absorbance of the colored end-product is monitored at 405 nm for 200 s using a V max Kinetic Microplate Reader (Molecular Devices, Menlo Park, CA), which automatically calculates the rate of substrate conversion (mOD/min). To measure the ability of BCX 1470 to inhibit the esterolytic activity of factor D, C1s, and trypsin, the inhibitor was added to 100 l of assay buffer already containing the target enzyme. Substrate (100 l) was then added and its conversion was monitored. Negative control wells received buffer, substrate, and inhibitor but no enzyme. The IC 50 value for esterolysis was calculated from semilogarithmic plots of percent inhibition of esterolysis vs concentration of inhibitor, with percent inhibition defined as: [(rate of esterolysis in absence of inhibitor Ϫ rate of esterolysis in the presence of inhibitor) Ϭ (rate of esterolysis in absence of inhibitor)] ϫ 100.
Hemolytic assays
Total classical pathway hemolytic activity of human and rat serum was measured by mixing 100 l rabbit Ab-sensitized sheep erythrocytes (1.5 ϫ 10 8 /ml) with 100 -600 l of an appropriate dilution of serum in GVB 2ϩ (veronal-buffered saline (pH 7.3) containing 1 mM MgC1 2 , 0.15 mM CaCl 2 , and 0.1% gelatin). The reaction volume was adjusted to 1.5 ml with GVB 2ϩ and the mixture was incubated for 60 min at 37°C. The absorbance of the supernatants at 413 nm was then used to calculate CH 50 U/ml. Total alternative pathway hemolytic activity of human serum was measured by mixing 250 l rabbit erythrocytes (1 ϫ 10 8 /ml) with 50 -150 l of a 1/10 dilution of serum in DGBV-Mg-EGTA (half-strength veronal-buffered saline (pH 7.3) containing 2.5% dextrose, 2.5 mM MgC1 2 , 10 mM EGTA, and 0.1% gelatin). DGVB-Mg-EGTA was added to a final volume of 500 l, and the mixture was incubated for 60 min at 37°C. The hemolytic reaction was stopped by adding 2 ml ice-cold DGVB-EDTA (DGVB containing 10 mM EDTA) and the absorbance of the supernatants at 413 nm was used to calculate AP 50 U/ml. To measure alternative pathway activity of rat serum, guinea pig erythrocytes were substituted for rabbit erythrocytes. To assess inhibition of classical or alternative pathway hemolytic activity by BCX 1470, dilutions of the inhibitor in 100 l buffer were added to titration mixtures before adjusting the final volume. Percent inhibition was calculated from controls without inhibitor and used to determine IC 50 values.
Factor D hemolytic activity was measured by using neuraminidasetreated sheep erythrocytes carrying human C3b (EC3b), prepared as described (17) . Mixtures of 2.5 ϫ 10 6 EC3b, 250 ng factor B, 6 ng properdin, and variable amounts (0.1-8.0 ng) of factor D in a total volume of 150 l DGVB-Mg-EGTA were incubated at 30°C for 15 min to allow formation of EC3bBb(P). The reaction was stopped by adding 1.0 ml GVB-EDTA (veronal-buffered saline (pH 7.3) containing 10 mM EDTA and 0.1% gelatin), and the cells were pelleted and resuspended in 50 l GVB-EDTA. Convertase sites were developed by adding 350 l guinea pig serum diluted 1/40 in GVB-EDTA and were incubated for 60 min at 37°C. Factor D hemolytic activity was then calculated (18) in U/ng from the absorbance of the supernatants at 413 nm. To assess inhibition of factor D hemolytic activity by BCX 1470, an amount of factor D corresponding to 1 hemolytic unit (1-2 ng of factor D depending on the batch of EC3b cells) was incubated with variable amounts of the inhibitor at 30°C for 30 min, and residual factor D activity was measured. Percent inhibition was calculated from controls without inhibitor and used to determine IC 50 values. To assess inhibition of factor B hemolytic activity, EC3bBb(P) cells carrying an average of one hemolytic site per cell were incubated with variable amounts of BCX 1470 in a final volume of 100 l GVB-EDTA at 30°C for 10 min. Residual sites were then developed with guinea pig serum diluted 1/40 in GVB-EDTA and used to calculate IC 50 values.
Arthus reactions
Animals were anesthetized by i.p. injection of a mixture of ketamine and xylazine (Fort Dodge Laboratories, Fort Dodge, IA), and the medial surface of both hind legs and the back was shaved. Chicken egg albumin (6.6 mg/ml) in sterile 0.9% NaCl containing 2% Evans blue dye was injected into the left femoral vein of each animal (10 mg OVA/kg). Five minutes later, the indicated amounts of rabbit IgG anti-chicken egg albumin in 25 l of 0.9% NaCl was injected intradermally. Control sites received 25 l of 0.09% NaCl. Before injection of OVA or Ab, any aggregates were removed by centrifugation at 12,000 ϫ g for 5 min. Each animal's skin was injected with IgG at two sites and with saline at two sites. All intradermal injections were spaced no more than 2 cm apart and were confined to the upper two-thirds of the trunk. At various times after initiation of the RPA reaction, blood was collected for determination of serum hemolytic activity or the animals were killed by CO 2 asphyxiation. The injected area of skin was harvested for quantitation of lesion size and was further processed for histology.
The area of the dermis stained by extravasation of Evans blue dye was used to quantitate the degree of inflammation elicited by the RPA reaction. Immediately after harvest, the skins were everted, overlaid with transparent plastic film, and the perimeter of each blue lesion was traced using an electronic hand-held digitizer that automatically calculates the area (in cm 2 ) of each lesion. The net area of lesions was determined by subtracting the average area of lesions generated by injection of saline from the area of each IgG-injected lesion.
Hypocomplementemia was induced via i.p. injection of CoVF (30 g) (19) 18 h before initiation of RPA reactions. We have shown (20) using ELISA (21) that this treatment reduces mouse serum antigenic C3 to less than 3% of initial levels within 4 h, and that the hypocomplementemic condition persists for at least 48 h. We verified that after injection of CoVF, antigenic C3 was also not detected in rat and guinea pig sera collected up to 24 h after CoVF treatment (data not shown). To test whether administration of BCX 1470 inhibits the RPA reaction, the compound was mixed with the OVA/dye solution and administered i.v. to rats (10 mg/kg) via the right femoral vein immediately before initiation of dermal RPA reactions. Alternatively, BCX 1470 was infused during the initial hour of the RPA reaction (0.25 mg/kg final dose), beginning immediately after injection of OVA and just before dermal injection of Ab. Preliminary tests confirmed that 24-h survival of rats treated with 10 mg/kg of BCX 1470 was 100%. Control rats (no inhibitor) received a bolus or an infusion of 5% dextrose.
Histology
Skin biopsies were taken from saline-injected and Ab-injected sites, embedded in OCT compound (Sakura Fineteck USA, Torrance, CA), flash frozen in liquid nitrogen, and stored frozen (at Ϫ70°C) until processed. Serial sections (4 m) were cut from each lesion on a cryostat microtome set at Ϫ20°C, beginning at the periphery of each lesion and ending proximal to but not including the point of injection. Sections were mounted on glass slides, air dried, acetone fixed, and stained with hematoxylin and eosin to visualize overall tissue pathology. To reveal ICs and the extent of deposition of C3, sections were blocked with normal horse serum and double stained with tetramethyl rhodamine isothyocyanate (TRITC)-labeled goat F(abЈ) 2 
Statistical analysis
Significant differences were determined by Student's t tests. Statistical significance was defined as p Ͻ 0.05. All averaged values are expressed as the mean Ϯ SEM.
Results
Requirement of complement in the RPA reaction is species specific
To determine whether the role of complement in IC-initiated inflammatory reaction is species specific in rodents and to identify an appropriate animal model for testing complement inhibitors in vivo, we compared the RPA reaction in the skin of rats, guinea pigs, and mice. Under identical experimental conditions, intradermal injection of IgG anti-chicken egg albumin (50 g) into animals receiving i.v. 10 mg/kg of chicken egg albumin elicited inflammatory skin lesions in all three rodent species (Fig. 1) . As judged by similar lesion size, the inflammatory response was of comparable intensity in rats and mice but was much more pronounced in guinea pigs (Fig. 1) . The intensity of the RPA response was reduced significantly (6-fold) in rats made hypocomplementemic by injection of CoVF and was also reduced significantly (2-fold) in hypocomplementemic guinea pigs (Fig. 1) . In contrast, the size of RPA lesions elicited in mice was not reduced by CoVFinduced hypocomplementemia (Fig. 1) . Thus, in rodents, sensitivity to RPA-induced extravasation is species specific, and in rats and guinea pigs, but not in mice, complement appears to be a major mediator of the inflammatory response.
Kinetics and dose response of the rat RPA reaction
Because the net effect of hypocomplementemia on the RPA response was greatest in the rat, we studied in more detail the kinetics and IgG dose responsiveness of the reaction in this species. As shown in Fig. 2 , dermal lesions are already of substantial size by 2 h after injection of 20 g IgG Ab, and typically they attain maximum size within 3-4 h. Beyond 4 h there is gradual regression of the size of the lesions, although they are still obvious even at 18 h. The intensity of the dermal edema increased with the amount of injected IgG (Fig. 3) . A strict requirement for complement was confirmed by the fact that hypocomplementemic rats showed no significant edema development even when 100 g of IgG was used (Fig. 3) . The dermal edema elicited by this dose of Ab in hypocomplementemic rats was not significantly greater than that elicited in control rats by injection of saline (Fig. 3) .
Microscopic examination of skin biopsies from normocomplementemic rats revealed extensive edema of the hypodermis at the sites of Ab injection (Fig. 4B) , whereas saline-injected skin showed normal histology (Fig. 4A) . Immunofluoresence confirmed the presence of ICs in Ab-injected sites (Fig. 5) . These contained rabbit IgG (Fig. 5B) , chicken egg albumin (Fig. 5C) , and extensive deposits of C3 (Fig. 5B) . By comparison, in the dermis of hypocomplementemic rats, IgG was deposited (Fig. 6C ) but C3 was not (Fig. 6D) . These combined data indicate that in the rat during the first 4 h of the RPA reaction, the dermal inflammatory response requires the deposition of ICs and an intact serum complement system. FIGURE 1. Species-specific requirement of complement in the RPA reaction. Rats, guinea pigs, and mice were injected i.v. with 10 mg/kg of chicken egg albumin in 2% Evans blue dye, after which they immediately received an intradermal injection of saline or 50 g of rabbit IgG antichicken egg albumin (25 l per site). The Arthus reaction was allowed to proceed for 4 h, and the net area of each IgG-induced dermal lesion was determined as described in Materials and Methods. To deplete serum complement, animals were injected i.p. with 30 g CoVF 18 h before initiation of the RPA reaction. Control animals received no CoVF treatment. The data are presented as the mean Ϯ SEM from three experiments, n ϭ 3-4 animals (6 -8 lesions) per group. ‫,ء‬ p Ͻ 0.009 vs untreated group (Student's t test). ns, not significant.
BCX 1470 inhibits complement activation in vitro and blocks the Arthus reaction in vivo
The serine protease inhibitor BCX 1470 inhibits the esterolytic activity of factor D and C1s 3.4-and 200-fold better, respectively, than that of trypsin (Table I ). The ability of BCX 1470 to inhibit esterolytic activity translates into potent inhibition of the proteolytic activity of C1s, factor D, and consequently of the classical and alternative pathway-mediated hemolysis of target RBC (Table  I) . As expected from its more effective inhibition of C1s esterolytic activity, classical pathway hemolytic activity is inhibited 7-fold more effectively than that of the alternative pathway. Inhibition of the alternative pathway is apparently due to inhibition of factor D and not factor B (Table I) .
We tested the ability of BCX 1470 to inhibit development of the rat dermal RPA reaction. BCX 1470 administered i.v. as either a single bolus or a 1-h infusion significantly reduced edema (Fig. 7) . Remarkably, the inhibition of edema development achieved by 1-h infusion of BCX 1470 was equivalent to that achieved by induction of hypocomplementemia with CoVF (Fig. 7) . Evidence that the mode of action of BCX 1470 in vivo involves inhibition of complement activity was obtained by serial measurements of serum hemolytic activity during development of RPA lesions (Fig.  8) . During the RPA reaction in control rats, no significant change in serum classical pathway hemolytic activity was detected, but alternative pathway hemolytic activity decreased by 50% (Fig.  8A) . By comparison, in rats infused for 1 h with BCX 1470 the FIGURE 4. Tissue response in the rat RPA reaction. RPA reactions were allowed to proceed in rats for 4 h before preparation of skin biopsies from a saline-injected site (A) and a site injected with 25 g of IgG (B) on the same animal. In the IgGinjected site there is extensive separation of the collagen fibers due to edema in the hypodermis (h). The abbreviations used are as follows: m, muscle; d, dermis; f, hair follicle. Hematoxylin and eosin stain. Original magnification ϫ32. FIGURE 5. Ab, Ag, and complement are present in immune complexes formed during the rat RPA reaction. An RPA reaction was allowed to proceed in the skin of a single rat for 4 h before preparation of skin biopsies from sites injected with saline (A) or 25 g of IgG (B and C). Immunofluorescence staining was performed using TRITC-labeled anti-rabbit IgG (red), FITC-labeled anti-rat C3 (green), and FITC-labeled anti-chicken egg albumin (green). Large immune complexes with extensive deposits of rat C3 are found in IgG-injected sites (B, yellow staining indicates co-localization of IgG and C3). C, An adjacent section through the same lesion shown in B, stained for chicken OVA (green) and rabbit IgG (red). No rabbit IgG-specific fluorescence and scant rat C3-specific fluorescence is seen in the saline-injected site (A). Original magnification ϫ64.
decrease in alternative pathway activity was delayed by at least 2.5 h (Fig. 8B) . Based on the in vitro data, we suggest that BCX 1470 abbrogates the RPA reaction in rats via blockade of complement activation, most likely via inactivation of C1s and factor D enzymatic activity.
Discussion
Two major conclusions can be drawn from these data. First, in rodents the contribution of complement to RPA-induced dermal edema is species specific. Complement is necessary in rats and guinea pigs but not in mice. Second, the serine protease inhibitor BCX 1470 blocks development of RPA-induced edema in the rat, apparently by inhibiting complement activation.
Our data support the proposal that complement-mediated processes are of major importance in the RPA reaction in rats (22) . The weak dermal response we observed in hypocomplementemic rats after administration of a high dose of Ab and the weak RPA reaction seen by others in rats treated with the complement inhibitor soluble complement receptor type I, sCR1 (22) , suggest that complement-independent processes do not make a significant contribution to the initial increased vascular permeability of the RPA reaction. Our data show that guinea pigs are more sensitive to IC-mediated inflammation than rats, but the contribution of complement is likely similar in these two species. In contrast, complement has little or no effector role in RPA reaction in C57BL/6J mice. Thus, our data do not contradict the proposal (23) that in mice, complement is not required for IC-mediated inflammation. However, because only C57BL/6J mice were used in our work, we cannot exclude the possibility of complement participation in the dermal RPA reaction in other strains of mice. In fact, soon after the initial submission of this paper, it was reported that the major mechanism promoting immune complex-triggered peritonitis in C57BL/6J mice was activation of macrophages via Fc␥RI, whereas in BALB/c mice the response was complement dependant (24) .
The rat RPA reaction has often been used as an in vivo model to test the efficacy of anti-inflammatory drugs (25) (26) (27) (28) (29) (30) (31) ). Yet, despite FIGURE 6. IgG is deposited in the absence of complement in RPA lesions in CoVF-treated rats. The RPA reaction was initiated in normocomplementemic (A and B) and CoVF-treated hypocomplementemic rats (C and D) . At 4 h, skin biopsies were prepared and stained with TRITC anti-rabbit IgG (red) and FITC anti-rat C3 (green). IgG is deposited in the hypodermis of both control (A) and hypocomplementemic rats (C). In contrast, C3 is deposited in control (B) but not in hypocomplementemic rats (D). The abbreviations used are as follows: h, hypodermis; f, hair follicle. Original magnification ϫ32. these efforts, an extensive literature search suggests that ours is the first study to quantitate the effects of an RPA reaction on the activity of serum complement. Despite evidence that ICs activate the classical pathway in vitro (32), we detected no change in rat serum classical pathway hemolytic titers during the dermal RPA reaction. In contrast, the serum alternative pathway hemolytic activity decreased significantly during the rat RPA response. We do not know the reason for this discrepancy. The results of both hemolytic assays depend on the levels of C3 to C9, although not necessarily to the same extent. Therefore, the observed difference could be due either to a greater degree of activation/consumption of factor B than C2 and/or C4, or to different sensitivities of the two assays to decreased levels of C3 to C9. We have shown that the synthetic serine protease inhibitor BCX 1470 is a potent inhibitor of C1s and factor D in vitro and that it prevents the initial phase of IC-mediated inflammation in rats and the associated systemic complement activation. We did not exhaustively investigate the effects of the inhibitor on tissue deposition of the various complement components during the Arthus reaction, but presumably deposition of C1q is not affected, whereas deposition of later components (e.g., C3, C4, and C5b-9) is reduced. Also we cannot exclude the possibility that the BCX 1470 effects on RPA were at least in part due to inhibition of some other serine protease. However, taken together with the results of the CoVF decomplementation experiments, these results support the conclusion that complement is necessary for the development of RPA lesions in rat skin. Although the role of complement in ICmediated diseases may differ in rats and humans, BCX 1470 or other similar protease inhibitors have potential medical applications in the pharmacologic control of complement activation in human diseases.
FIGURE 8.
Reduction of serum alternative pathway hemolytic activity during the rat RPA is delayed by infusion of BCX 1470. Before and up to 4 h after initiation of an RPA reaction in rats, blood was collected and the sera were used to determine CH 50 (E) and AP 50 (F). In control rats infused with dextrose (A), no significant change in CH 50 was detected, and AP 50 decreased significantly below baseline levels by 2.5 h ‫,ء(‬ p Ͻ 0.05, Student's t test). In contrast, in rats infused with BCX 1470 (B), the reduction in AP 50 was delayed for 4 h. The data are presented as the mean Ϯ SEM for two experiments, n ϭ 4 -8 lesions (2-4 rats) per time point.
